Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003433211 | Liver | HCC | adherens junction organization | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
GO:003223122 | Liver | HCC | regulation of actin filament bundle assembly | 57/7958 | 105/18723 | 9.73e-03 | 3.66e-02 | 57 |
GO:00070158 | Lung | IAC | actin filament organization | 92/2061 | 442/18723 | 1.01e-09 | 1.93e-07 | 92 |
GO:00510178 | Lung | IAC | actin filament bundle assembly | 40/2061 | 157/18723 | 2.66e-07 | 2.14e-05 | 40 |
GO:00329708 | Lung | IAC | regulation of actin filament-based process | 77/2061 | 397/18723 | 4.85e-07 | 3.10e-05 | 77 |
GO:00615728 | Lung | IAC | actin filament bundle organization | 40/2061 | 161/18723 | 5.43e-07 | 3.32e-05 | 40 |
GO:00329568 | Lung | IAC | regulation of actin cytoskeleton organization | 70/2061 | 358/18723 | 1.17e-06 | 6.20e-05 | 70 |
GO:19029038 | Lung | IAC | regulation of supramolecular fiber organization | 73/2061 | 383/18723 | 1.87e-06 | 8.87e-05 | 73 |
GO:00605624 | Lung | IAC | epithelial tube morphogenesis | 63/2061 | 325/18723 | 5.28e-06 | 2.07e-04 | 63 |
GO:00322318 | Lung | IAC | regulation of actin filament bundle assembly | 28/2061 | 105/18723 | 6.21e-06 | 2.30e-04 | 28 |
GO:00452168 | Lung | IAC | cell-cell junction organization | 43/2061 | 200/18723 | 1.21e-05 | 3.64e-04 | 43 |
GO:01100538 | Lung | IAC | regulation of actin filament organization | 54/2061 | 278/18723 | 2.27e-05 | 6.28e-04 | 54 |
GO:00439545 | Lung | IAC | cellular component maintenance | 17/2061 | 61/18723 | 2.24e-04 | 3.89e-03 | 17 |
GO:00016554 | Lung | IAC | urogenital system development | 59/2061 | 338/18723 | 2.27e-04 | 3.93e-03 | 59 |
GO:00343325 | Lung | IAC | adherens junction organization | 13/2061 | 49/18723 | 1.95e-03 | 1.97e-02 | 13 |
GO:00506735 | Lung | IAC | epithelial cell proliferation | 68/2061 | 437/18723 | 2.05e-03 | 2.05e-02 | 68 |
GO:00720014 | Lung | IAC | renal system development | 50/2061 | 302/18723 | 2.13e-03 | 2.11e-02 | 50 |
GO:00721604 | Lung | IAC | nephron tubule epithelial cell differentiation | 6/2061 | 14/18723 | 2.42e-03 | 2.33e-02 | 6 |
GO:00018223 | Lung | IAC | kidney development | 48/2061 | 293/18723 | 3.19e-03 | 2.77e-02 | 48 |
GO:00720734 | Lung | IAC | kidney epithelium development | 26/2061 | 136/18723 | 3.50e-03 | 2.96e-02 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTSS1 | SNV | Missense_Mutation | | c.923C>G | p.Ser308Cys | p.S308C | O43312 | protein_coding | tolerated(0.11) | probably_damaging(1) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MTSS1 | SNV | Missense_Mutation | | c.294C>A | p.Ser98Arg | p.S98R | O43312 | protein_coding | tolerated(0.06) | probably_damaging(0.988) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
MTSS1 | SNV | Missense_Mutation | | c.1084N>A | p.Glu362Lys | p.E362K | O43312 | protein_coding | tolerated(0.46) | benign(0.182) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MTSS1 | SNV | Missense_Mutation | rs762528178 | c.1930N>T | p.Arg644Trp | p.R644W | O43312 | protein_coding | tolerated(0.18) | possibly_damaging(0.84) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MTSS1 | SNV | Missense_Mutation | | c.252G>A | p.Met84Ile | p.M84I | O43312 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MTSS1 | SNV | Missense_Mutation | novel | c.1532N>T | p.Thr511Ile | p.T511I | O43312 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MTSS1 | SNV | Missense_Mutation | novel | c.1268N>C | p.Asp423Ala | p.D423A | O43312 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A204-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTSS1 | SNV | Missense_Mutation | rs149780096 | c.1395N>A | p.Met465Ile | p.M465I | O43312 | protein_coding | tolerated(0.46) | benign(0.023) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTSS1 | SNV | Missense_Mutation | novel | c.421N>G | p.Ser141Ala | p.S141A | O43312 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
MTSS1 | insertion | Nonsense_Mutation | novel | c.1292_1293insAAAAAATAATAATAAATAAA | p.Arg432LysfsTer6 | p.R432Kfs*6 | O43312 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |